Kimberly L. Blackwell
Advanced in Triple-Negative Breast Cancer

Dr. Kimberly L. Blackwell

Hematology Oncology
Duke South I Trent Dr, Campus Box 3893, 
Durham, NC 
Advanced in Triple-Negative Breast Cancer
Duke South I Trent Dr, Campus Box 3893, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kimberly Blackwell is a Hematologist Oncology provider in Durham, North Carolina. Dr. Blackwell is rated as an Advanced provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Agranulocytosis, and Paget Disease of the Breast.

Her clinical research consists of co-authoring 77 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 3 clinical trials in the study of Triple-Negative Breast Cancer.

Specialties
Hematology Oncology
Licenses
Internal Medicine in NC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Duke South I Trent Dr, Campus Box 3893, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases
A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases
Enrollment Status: Completed
Publish Date: January 23, 2026
Intervention Type: Drug, Procedure
Study Drugs: HKI-272, Capecitabine, Ado-Trastuzumab Emtansine
Study Phase: Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drugs: Olaparib, durvalumab
Study Phase: Phase 2
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 17, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-Expressing, Triple Negative Breast Cancer (TNBC) With Residual Disease Post Standard Neoadjuvant Chemotherapy
Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-Expressing, Triple Negative Breast Cancer (TNBC) With Residual Disease Post Standard Neoadjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: July 05, 2018
Intervention Type: Drug
Study Phase: Phase 1
Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis
Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis
Enrollment Status: Terminated
Publish Date: February 28, 2018
Intervention Type: Drug
Study Phase: Phase 1
CSF Pharmacokinetics of Systemic Anti-Cancer Therapies in Patients With Advanced Cancer
CSF Pharmacokinetics of Systemic Anti-Cancer Therapies in Patients With Advanced Cancer
Enrollment Status: Terminated
Publish Date: February 28, 2018
Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy
Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy
Enrollment Status: Withdrawn
Publish Date: June 05, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

78 Total Publications

Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers.
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers.
Journal: NPJ precision oncology
Published: May 09, 2024
Similar Doctors
Distinguished in Triple-Negative Breast Cancer
Dr. Benjamin G. Vincent
Hematology Oncology | Hematology | Oncology
Distinguished in Triple-Negative Breast Cancer
Dr. Benjamin G. Vincent
Hematology Oncology | Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.6 miles away)
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Benjamin Vincent is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Vincent has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Triple-Negative Breast Cancer, Acute Myeloid Leukemia (AML), NUT Carcinoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vincent is currently accepting new patients.

Distinguished in Triple-Negative Breast Cancer
Dr. Jonathan S. Serody
Hematology Oncology | Hematology | Oncology
Distinguished in Triple-Negative Breast Cancer
Dr. Jonathan S. Serody
Hematology Oncology | Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.6 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jonathan Serody is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Serody is rated as a Distinguished provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Serody is currently accepting new patients.

Advanced in Triple-Negative Breast Cancer
Dr. Jeremy M. Force
Hematology Oncology | Hematology | Oncology
Advanced in Triple-Negative Breast Cancer
Dr. Jeremy M. Force
Hematology Oncology | Hematology | Oncology
10 Bryan Searle Drive Seeley Mudd Building Room 449b, 
Durham, NC 
 (2.2 miles away)
919-613-6891
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jeremy Force is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Force is rated as a Distinguished provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Force is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Blackwell's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile